RecruitingNot ApplicableNCT06930807

Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer

Sponsor

Peking University People's Hospital

Enrollment

1,000 participants

Start Date

Mar 25, 2025

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Minimal Residual Disease Adaptive Treatment

Summary

The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are: * How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer? * Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival? * Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a "liquid biopsy" — a blood test that detects tiny fragments of tumor DNA — can help doctors detect cancer recurrence after surgery for early-stage non-small cell lung cancer (NSCLC). The goal is to catch recurrence earlier and guide follow-up care. **You may be eligible if...** - You have been diagnosed with early-to-intermediate stage non-small cell lung cancer (Stage IA–IIIA) - You are planning to have curative surgery or pre-surgery (neoadjuvant) therapy - You have not had another type of cancer in the past 5 years - Your tumor tissue and imaging records are accessible **You may NOT be eligible if...** - You are under 18 years old - Your lung cancer is at a more advanced stage (Stage IIIB–IV) - Your tumor turns out not to be non-small cell lung cancer after surgery - You have had another type of cancer in the past 5 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAdaptive postoperative management based on minimal residual disease

participants will not receive postoperative treatment if (neoadjuvant therapy efficacy reaches pCR and) MRD results keep negative.

Locations(1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06930807

Related Trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738301 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT0606804925 locations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386299 locations

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT028388361 location